AstraZeneca Pharma India Limited — Important, 21-07-2025: Updates

AstraZeneca has issued a communication to shareholders regarding tax deduction at source (TDS) on the dividend for the financial year 2024-25, following the Board's dividend approval. For resident shareholders, 10% TDS will apply (20% if PAN is invalid or not linked to Aadhaar), unless a valid Form 15G/15H is submitted and dividend is below Rs. 5,000. Non-resident shareholders can claim Double Taxation Avoidance Agreement (DTAA) benefits by submitting required documents. This impacts the net dividend received by investors.